[go: up one dir, main page]

AR076570A1 - Moleculas de union humanas capaces de neutralizar el virus de la influenza h3n2 y usos de las mismas - Google Patents

Moleculas de union humanas capaces de neutralizar el virus de la influenza h3n2 y usos de las mismas

Info

Publication number
AR076570A1
AR076570A1 ARP100101631A ARP100101631A AR076570A1 AR 076570 A1 AR076570 A1 AR 076570A1 AR P100101631 A ARP100101631 A AR P100101631A AR P100101631 A ARP100101631 A AR P100101631A AR 076570 A1 AR076570 A1 AR 076570A1
Authority
AR
Argentina
Prior art keywords
influenza virus
antibodies
neutralizing
same
influenza
Prior art date
Application number
ARP100101631A
Other languages
English (en)
Inventor
Mark Throsby
Robert H E Friesen
Theodorus H J Kwaks
Mandy A C Jongeneelen
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of AR076570A1 publication Critical patent/AR076570A1/es

Links

Classifications

    • C07K16/108—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente solicitud se relaciona con moléculas de union, tales como anticuerpos monoclonales humanos que se unen a distintos virus de la influenza que comprenden HA del subtipo H3, tales como H3N2, y que tienen una amplia actividad neutralizante contra dicho virus de la influenza. Se proveen moléculas de ácido nucleico que codifican los anticuerpos, sus secuencias y composiciones que los comprenden y métodos para identificarlos y producirlos. Los anticuerpos se pueden usar en el diagnostico, profilaxis y/o tratamiento de una infeccion por el virus de la influenza H3N2. En una realizacion preferida, los anticuerpos proveen proteccion cruzada contra distintos subtipos, de modo tal que se pueden prevenir y/o tratar infecciones por subtipos de influenza basados en H3, H7, y/o H10.
ARP100101631A 2009-05-11 2010-05-11 Moleculas de union humanas capaces de neutralizar el virus de la influenza h3n2 y usos de las mismas AR076570A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21589009P 2009-05-11 2009-05-11
EP09159947 2009-05-11
EP10151155 2010-01-20

Publications (1)

Publication Number Publication Date
AR076570A1 true AR076570A1 (es) 2011-06-22

Family

ID=42271865

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101631A AR076570A1 (es) 2009-05-11 2010-05-11 Moleculas de union humanas capaces de neutralizar el virus de la influenza h3n2 y usos de las mismas

Country Status (19)

Country Link
US (2) US8470327B2 (es)
EP (1) EP2430046B1 (es)
JP (2) JP5813629B2 (es)
KR (1) KR101790354B1 (es)
CN (2) CN102448986B (es)
AR (1) AR076570A1 (es)
AU (1) AU2010247530B2 (es)
BR (1) BRPI1012749B1 (es)
CA (1) CA2761648C (es)
CU (1) CU23938B1 (es)
EA (1) EA029939B8 (es)
ES (1) ES2934102T3 (es)
IL (1) IL216222A (es)
MX (1) MX2011011331A (es)
MY (1) MY183517A (es)
NZ (1) NZ596032A (es)
SG (1) SG176003A1 (es)
TW (1) TWI589300B (es)
WO (1) WO2010130636A1 (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100480260C (zh) 2002-07-18 2009-04-22 克鲁塞尔荷兰公司 抗体混合物的重组生产
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
JP5161882B2 (ja) 2006-09-07 2013-03-13 クルセル ホランド ベー ヴェー インフルエンザウイルスｈ５ｎ１を中和しうるヒト結合性分子およびその使用
CA2708221C (en) 2007-12-06 2017-07-25 Wayne A. Marasco Antibodies against influenza virus and methods of use thereof
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
AU2010247530B2 (en) 2009-05-11 2016-10-13 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
KR20120132506A (ko) 2010-02-18 2012-12-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 질환의 예방 및 치료에 사용되는 백신
US9708373B2 (en) 2010-03-30 2017-07-18 Icahn School Of Medicine At Mount Sinai Influenza virus vaccine and uses thereof
US9707288B2 (en) 2010-07-22 2017-07-18 John W. Schrader Cross-protective pathogen protection, methods and compositions thereof
PH12013500204A1 (en) 2010-08-03 2013-04-01 Univ Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
WO2012145572A1 (en) 2011-04-20 2012-10-26 The Trustees Of The University Of Pennsylvania Regimens and compositions for aav-mediated passive immunization of airborne pathogens
EA027054B1 (ru) 2011-07-14 2017-06-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирусы гриппа a филогенетической группы 1 и филогенетической группы 2 и вирусы гриппа b
CN108164602A (zh) 2011-09-20 2018-06-15 西奈山医学院 流感病毒疫苗及其应用
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
CA2852474A1 (en) 2011-10-18 2013-04-25 Emory University Antibodies directed against influenza
CA2857087C (en) * 2011-11-28 2021-05-25 Crucell Holland B.V. Influenza virus vaccines and uses thereof
KR20130059721A (ko) * 2011-11-29 2013-06-07 (주)셀트리온 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자
JP6325451B2 (ja) * 2011-12-02 2018-05-16 アイム・セラピューティクス・べー・フェー Ａ型インフルエンザに特異的な抗体
EP2793945B1 (en) 2011-12-05 2018-08-15 Trellis Bioscience, LLC Antibodies useful in passive influenza immunization
WO2013132007A1 (en) * 2012-03-08 2013-09-12 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
US9388217B2 (en) 2012-03-13 2016-07-12 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
EP2712626A1 (en) 2012-09-28 2014-04-02 Fabentech Passive immunisation against influenza, in particular H5N1
ES2701746T3 (es) 2012-11-13 2019-02-25 Hoffmann La Roche Anticuerpos antihemaglutinina y procedimientos de uso
CN108641002A (zh) 2012-12-18 2018-10-12 西奈山伊坎医学院 流感病毒疫苗及其用途
EP2970397A2 (en) 2013-03-14 2016-01-20 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
WO2014159960A1 (en) * 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EP3003373A4 (en) 2013-03-14 2016-10-19 Contrafect Corp COMPOSITION AND METHODS BASED ON INTRANASALLY RELEASED NEUTRALIZING ANTIBODIES FOR IMPROVED THERAPEUTIC EFFECTIVENESS
US9649375B2 (en) 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
KR20140118682A (ko) * 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
KR101511619B1 (ko) * 2013-04-30 2015-04-13 한국생명공학연구원 개 인플루엔자 바이러스 h3n2의 ha1 단백질을 항원으로 포함하는 개 인플루엔자 바이러스 h3n2에 특이적인 혈청 진단용 키트
AU2014273173B2 (en) 2013-05-30 2018-09-27 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
RU2682049C2 (ru) * 2014-01-27 2019-03-14 Дженентек, Инк. Лечение вируса гриппа а h7n9
WO2015120097A2 (en) 2014-02-04 2015-08-13 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
DK3105250T3 (da) 2014-02-10 2020-09-28 Igm Biosciences Inc Multispecifikke iga-bindingsmolekyler
WO2015143339A2 (en) 2014-03-21 2015-09-24 University Of Washington Enhanced influenza hemagglutinin binders
KR101628331B1 (ko) * 2014-03-28 2016-06-08 주식회사 녹십자엠에스 인플루엔자 a 바이러스 특이적 단클론 항체 및 이를 이용한 인플루엔자 감염 치료 및 진단 방법
PL3142750T3 (pl) 2014-05-13 2021-03-08 The Trustees Of The University Of Pennsylvania Kompozycje zawierające aav eksprymujące konstrukty podwójnych przeciwciał i ich zastosowania
MX378904B (es) 2014-07-10 2025-03-10 Janssen Vaccines & Prevention Bv Vacunas para virus influenza y usos de las mismas.
CN107074912B (zh) 2014-07-10 2021-10-29 扬森疫苗与预防公司 流行性感冒病毒疫苗及其用途
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
CN107750253B (zh) 2015-04-08 2022-10-04 达纳－法伯癌症研究所公司 人源化流感单克隆抗体及其使用方法
EP3307310A2 (en) 2015-05-13 2018-04-18 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-influenza antibodies and methods of use thereof
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2017147248A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
US11266734B2 (en) 2016-06-15 2022-03-08 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
CN106146657B (zh) * 2016-07-12 2020-07-17 晋明(天津)生物医药技术开发有限公司 广谱结合流感病毒a的重组抗体片段及其制备方法与应用
JP2020510430A (ja) 2017-02-28 2020-04-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ａａｖベクターに基づくインフルエンザワクチン
AU2018227440B2 (en) 2017-02-28 2024-06-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clade f vector and uses therefor
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
JP7009625B2 (ja) * 2017-10-18 2022-01-25 シァメン・ユニヴァーシティ Ｈ３ｎ２亜型インフルエンザウイルスのヘマグルチニンタンパク質の突然変異体及びその使用
RS63526B1 (sr) * 2018-01-23 2022-09-30 Janssen Vaccines & Prevention Bv Vakcine za virus gripa i njihove upotrebe
SG11202006379UA (en) 2018-01-26 2020-07-29 Regeneron Pharma Human antibodies to influenza hemagglutinin
WO2019246363A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
WO2020198329A1 (en) 2019-03-25 2020-10-01 Visterra, Inc. Compositions and methods for treating and preventing influenza
JP2022547107A (ja) 2019-09-05 2022-11-10 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザウイルスワクチン及びその使用
WO2021055679A1 (en) * 2019-09-20 2021-03-25 Academia Sinica Chimeric hemagglutinin protein and a vaccine composition comprising the same
CA3098079C (en) * 2019-12-13 2023-06-20 Autonomous Medical Devices Inc. Apparatus and method for point-of-care, rapid, field-deployable diagnostic testing of covid-19, viruses, antibodies and markers
US11642407B2 (en) 2020-02-28 2023-05-09 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
KR20230117157A (ko) 2020-12-01 2023-08-07 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 조직 특이적 표적화 모티프를 갖는 신규 조성물 및 이를 포함하는 조성물
CN117881786A (zh) 2021-04-27 2024-04-12 世代生物公司 表达治疗性抗体的非病毒dna载体及其用途
JP2025509607A (ja) 2022-03-14 2025-04-11 ジェネレーション バイオ カンパニー 異種プライムブーストワクチン組成物及び使用の方法
EP4508077A1 (en) 2022-04-14 2025-02-19 Invisishield Technologies Ltd. Compositions for preventing or treating influenza infections
JP2025537776A (ja) 2022-11-14 2025-11-20 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザｂ型ウイルスワクチン及びその使用
US20250090650A1 (en) 2023-09-06 2025-03-20 Sanofi Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof
CN119775400B (zh) * 2024-12-03 2025-10-17 深圳市儿童医院 一种结合h3n2 ha蛋白的全人源单克隆抗体mz001和应用
CN119775398B (zh) * 2024-12-03 2025-10-10 深圳市儿童医院 一种结合h3n2 ha蛋白的全人源单克隆抗体和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DK0934526T3 (da) 1996-10-08 2003-05-05 Bisys B V U Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål
SI1161548T2 (sl) 1999-04-15 2010-02-26 Crucell Holland Bv Priprava rekombinantnega proteina v humani celici z uporabo sekvenc, ki kodirajo adenovirusni E1 protein
DK1402025T3 (da) 2001-06-15 2006-06-06 Crucell Holland Bv Kimære fager
DE102004037820A1 (de) * 2004-08-04 2006-03-16 Epcos Ag Elektrische Schaltung und Bauelement mit der Schaltung
EP2540820B1 (en) 2005-12-09 2018-01-10 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for influencing the stability of antibody producing cells
EP2024393A2 (en) * 2006-05-15 2009-02-18 Sea Lane Biotechnologies,llc. Neutralizing antibodies to influenza viruses
US8148085B2 (en) 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
JP5161882B2 (ja) * 2006-09-07 2013-03-13 クルセル ホランド ベー ヴェー インフルエンザウイルスｈ５ｎ１を中和しうるヒト結合性分子およびその使用
JP5305427B2 (ja) * 2007-01-11 2013-10-02 公立大学法人大阪府立大学 インフルエンザウイルスに対する抗体の産生方法
CN102046654A (zh) * 2007-03-13 2011-05-04 胡马斯有限公司 针对甲型流感病毒h5n1株系的抗体
US8383121B2 (en) * 2007-09-13 2013-02-26 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof
FR2921928B1 (fr) * 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
CA2708221C (en) * 2007-12-06 2017-07-25 Wayne A. Marasco Antibodies against influenza virus and methods of use thereof
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
AU2010247530B2 (en) 2009-05-11 2016-10-13 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof

Also Published As

Publication number Publication date
TW201043248A (en) 2010-12-16
US20120039898A1 (en) 2012-02-16
AU2010247530A1 (en) 2011-11-03
EA201171383A1 (ru) 2012-05-30
KR20120034628A (ko) 2012-04-12
MX2011011331A (es) 2011-11-18
CN102448986B (zh) 2015-11-25
CU23938B1 (es) 2013-08-29
IL216222A (en) 2016-11-30
CA2761648A1 (en) 2010-11-18
IL216222A0 (en) 2012-01-31
EP2430046B1 (en) 2022-09-28
BRPI1012749B1 (pt) 2022-01-11
US9611317B2 (en) 2017-04-04
US20150175677A9 (en) 2015-06-25
CU20110206A7 (es) 2012-10-15
TWI589300B (zh) 2017-07-01
CN105418757A (zh) 2016-03-23
WO2010130636A1 (en) 2010-11-18
SG176003A1 (en) 2011-12-29
AU2010247530B2 (en) 2016-10-13
EP2430046A1 (en) 2012-03-21
CA2761648C (en) 2019-03-12
JP2012526526A (ja) 2012-11-01
BRPI1012749A2 (pt) 2020-11-17
KR101790354B1 (ko) 2017-10-25
NZ596032A (en) 2013-09-27
JP2016040261A (ja) 2016-03-24
ES2934102T3 (es) 2023-02-16
EA029939B8 (ru) 2021-04-21
MY183517A (en) 2021-02-24
KR101790354B9 (ko) 2017-10-25
US8470327B2 (en) 2013-06-25
CN102448986A (zh) 2012-05-09
CN105418757B (zh) 2019-07-09
US20130309248A1 (en) 2013-11-21
BRPI1012749A8 (pt) 2021-03-09
EA029939B1 (ru) 2018-06-29
JP5813629B2 (ja) 2015-11-17

Similar Documents

Publication Publication Date Title
AR076570A1 (es) Moleculas de union humanas capaces de neutralizar el virus de la influenza h3n2 y usos de las mismas
MX360056B (es) Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
MX346206B (es) Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b.
AR084237A1 (es) Metodos para tratar virus de hepatitis c (hcv), composicion
MD20140035A2 (ro) Metodă de tratament al hepatitei virale C
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
UY33897A (es) Inhibidores del virus de la hepatitis c
ECSP14013315A (es) Inhibidores de aplicación viral
CL2016000805A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201591761A1 (ru) Композиции на основе наночастиц
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
MX350282B (es) Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas.
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
UY34066A (es) Inhibidores del virus de la hepatitis c
CR20160178A (es) Derivados de desoxinojirimicina y sus métodos de uso
BR112015001619A2 (pt) manosídeos multiméricos, um processo para a preparação dos mesmos e as suas utilizações como um medicamento
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
MX343198B (es) Moleculas de union humanas capaces de neutralizar el virus de la influenza h5n1 y usos de las mismas.
TR201910305T4 (tr) Viral enfeksiyonları tedavi etmek için bileşikler.
CU20140006A7 (es) Moléculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenético 1 y grupo filogenético 2 y virus de la influenza b
CL2012001269A1 (es) Compuestos derivados de bi-imidazol di-sustituidos; composicion farmaceutica que comprende a dicho compuesto; y su uso para tratar infecciones por virus de hepatitis c (vhc).

Legal Events

Date Code Title Description
FC Refusal